-
Mashup Score: 7Home | Lymphoma Hub - 2 day(s) ago
Online lymphoma resource for healthcare professionals, providing information, news & support relating to lymphoma, Hodgkin & non Hodgkin disease
Source: lymphomahub.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 7Home | Lymphoma Hub - 5 day(s) ago
Online lymphoma resource for healthcare professionals, providing information, news & support relating to lymphoma, Hodgkin & non Hodgkin disease
Source: lymphomahub.comCategories: General Medicine News, Oncologists1Tweet-
Data from the phase III STARGLO study presented at #EHA2024 found that Glofit-GemOx improved OS vs R-GemOx 📝 More news: https://t.co/Bj2BOQyiK7 #lymphoma #lymsm #MedNews #MedEd https://t.co/FuvBDVshNW
-
-
Mashup Score: 0
During the European Hematology Association (EHA) 2024 Hybrid Congress, the Lymphoma Hub was pleased to speak to Paolo Ghia, Vita-Salute San Raffaele, Milan, …
Source: www.youtube.comCategories: General Medicine News, Oncologists1Tweet-
Paolo Ghia @MyUniSR shares the latest updates from the SEQUOIA trial of zanubrutinib + venetoclax in treatment-naïve patients with CLL/SLL. Watch the full video here: https://t.co/wxstVk5l9c #lymsm #lymphoma #EHA2024 https://t.co/DTsHeO7hGz
-
-
Mashup Score: 2Lisocabtagene maraleucel vs standard of care as second-line therapy for LBCL: 3-year follow-up from the phase III TRANSFORM trial - 6 day(s) ago
We summarize results from the phase III TRANSFORM trial of liso-cel vs standard of care with salvage therapy followed by ASCT as second-line treatment for patients with LBCL presented at ASCO 2024 by Kamdar.
Source: lymphomahub.comCategories: General Medicine News, Oncologists1Tweet-
📝 Phase III results from the TRANSFORM trial presented at #ASCO24 provide new insights for #LBCL; see: https://t.co/dSY0haYrQX #lymphoma #lymsm #MedNews #MedEd @mana1981 https://t.co/JTklP1jN70
-
-
Mashup Score: 7Home | Lymphoma Hub - 7 day(s) ago
Online lymphoma resource for healthcare professionals, providing information, news & support relating to lymphoma, Hodgkin & non Hodgkin disease
Source: lymphomahub.comCategories: General Medicine News, Oncologists1Tweet-
Data from the phase III STARGLO study presented at #EHA2024 found that Glofit-GemOx improved OS vs R-GemOx 📝 More news: https://t.co/Bj2BOQyiK7 #lymphoma #lymsm #MedNews #MedEd https://t.co/FuvBDVshNW
-
-
Mashup Score: 0Outpatient administration of CAR T-cell therapies in patients with hematological malignancies - 8 day(s) ago
We summarize results from a retrospective analysis of reported outcomes of outpatient management of CAR T-cell therapies, with no remote monitoring and early intervention for CRS.
Source: lymphomahub.comCategories: General Medicine News, Oncologists1Tweet-
New publication 📝 Results from a retrospective analysis published in @BloodAdvances provide new insights for #lymphoma, see: https://t.co/AR2o8kdRGP #lymsm #MedNews https://t.co/iDnrtM9GP9
-
-
Mashup Score: 3Relmacabtagene autoleucel receives China NMPA supplementary biological application approval for R/R MCL - 12 day(s) ago
Following positive response data from the pivotal clinical trial in China, relmacabtagene autoleucel receives China NMPA supplementary biological application approval for the treatment of adult patients with R/R mantle cell lymphoma.
Source: lymphomahub.comCategories: General Medicine News, Oncologists1Tweet-
🚨 NEWS 🚨 China NMPA approves supplementary biological application of relmacabtagene autoleucel, an anti-CD19 CAR T-cell therapy, for the treatment of adult patients with R/R MCL after ≥2 prior lines of systemic therapy. 👉 https://t.co/NO8FrGCLGK #lymsm #lymphoma #MedNews https://t.co/jH0EOsML7u
-
-
Mashup Score: 7
Kothari et al. published results from the phase II PembroWM trial evaluating the efficacy and safety of pembrolizumab and rituximab combination and feasibility of PD-1 axis modulation in the treatment of #Waldenstrom’s macroglobulinemia.
Source: lymphomahub.comCategories: General Medicine News, Oncologists1Tweet-
New publication 📝 Phase II PembroWM trial results published in @BrJHaem provide new insights for relapsed/refractory #Waldenstrom’s macroglobulinemia, see: https://t.co/hMQ5uAenZ3 #lymphoma #lymsm https://t.co/NNHM0m7BZo
-
-
Mashup Score: 8
Odronextamab has received European Commission approval for patients with R/R FL or R/R DLBCL, following positive results from the ELM-1 and ELM-2 trials.
Source: lymphomahub.comCategories: General Medicine News, Oncologists1Tweet-
🚨NEWS 🚨 @EU_Commission approves odronextamab for adult patients with R/R #FL and R/R #DLBCL who progress after ≥2 prior systemic therapies. This decision is based on the supporting results from ELM-1 & ELM-2 trials. 👉 https://t.co/1ZroIxO7tt #lymsm #lymphoma #MedNews https://t.co/O3mqlbV2gE
-
-
Mashup Score: 7Home | Lymphoma Hub - 14 day(s) ago
Online lymphoma resource for healthcare professionals, providing information, news & support relating to lymphoma, Hodgkin & non Hodgkin disease
Source: lymphomahub.comCategories: General Medicine News, Oncologists1Tweet-
Data from the phase III STARGLO study presented at #EHA2024 found that Glofit-GemOx improved OS vs R-GemOx 📝 More news: https://t.co/Bj2BOQyiK7 #lymphoma #lymsm #MedNews #MedEd https://t.co/FuvBDVshNW
-
Data from the phase III STARGLO study presented at #EHA2024 found that Glofit-GemOx improved OS vs R-GemOx 📝 More news: https://t.co/Bj2BOQyiK7 #lymphoma #lymsm #MedNews #MedEd https://t.co/FuvBDVshNW